Billionaire investor Steven Cohen (Trades, Portfolio), who heads up hedge fund Point72 Asset Management, disclosed he upped his stake in Karyopharm Therapeutics Inc. (KPTI) on Feb. 22.

The guru’s Connecticut-based firm uses long, short, macro and systematic strategies to generate superior risk-adjusted returns.

According to GuruFocus real-time picks, a Premium feature, Cohen boosted his stake in the Newton, Massachusetts-based company by 127.39%, buying 1.96 million shares for an average price of $5.07 per share. He now holds 3.5 million shares. GuruFocus data shows he has lost approximately 28% on the investment since establishing it in the

Analysts took action on healthcare stocks on Thursday, May 24.

Cantor Fitzgerald initiated coverage of Apellis Pharmaceuticals, Inc. (APLS) with an ‘Overweight’ rating. The firm has set a price target on Apellis Pharmaceuticals of $52 per share. That is a 157% growth from the current market valuation of $20.23. The stock closed 2.9% up on May 24 and the market capitalization is $1.132 billion.

Cantor Fitzgerald’s estimate will drag the average target price up to about $38.6 per share of Apellis Pharmaceuticals from a previous mean value of $35.25 per share.

Currently the stock in Apellis Pharmaceuticals has a recommendation

Analogic Corp. (ALOG) announced that it has entered into a merger agreement with Altaris Capital Partners for $84.00 per share in cash, or approximately $1.1 billion on a fully diluted basis.

The agreement was unanimously approved by Analogic's board of directors. "The Board has always sought to maximize stockholder value," said Bernard Bailey, chairman of the Analogic board of directors. He added: "Given the increasingly competitive markets that we serve, we have been focused on the need to achieve greater scale in order to generate sustained profitable growth. As a result, the board initiated a review of strategic alternatives available

Point72 Asset Management founder Steven Cohen (Trades, Portfolio) established a holding in Karyopharm Therapeutics Inc. (KPTI) on Nov. 3, further expanding his large positioning in the health care space.

Managing a portfolio of 809 stocks, Cohen uses a bottom-up approach to identify discretionary long-short equities. The health care and consumer cyclical sectors compose the largest percentage of his portfolio.

Having previously exited a position in Karyopharm in the fourth quarter of 2014, Cohen purchased a 3.5 million-share stake for an average price of $11.23 per share. The trade had an impact of 0.22% on the portfolio.

The

The beginning of September has not been kind to American markets.

Some of the country’s biggest names have seen their stocks plummet for various reasons. The decrease in oil prices and the slowdown of American factories have definitely taken the wind out of their sails. Nonetheless, some companies, such as Vera Bradley (VRA), Charter Communications (CHTR) and even Karyopharm Therapeutics (KPTI) have managed to soar higher on good news.

Unfortunately, a larger number of companies experienced a dramatic downturn on Sept. 1. Five Below (FIVE), Bob Evans (BOBE) and Shoe Carnival (SCVL) have been hit hard by negative

According to GuruFocus Insider Data, these are the largest CEO sales during the past week: Karopharm Therapeuticcs Inc, Methode Electronics Inc, Gilead Sciences Inc, and Nimble Storage Inc.

Karyopharm Therapeutics Inc. (KPTI): CEO Michael Kauffman sold 200,000 Shares

CEO of Karyopharm Therapeutics Inc. (KPTI) Michael Kauffman sold 200,000 shares on 07/02/2014 at an average price of $42.5. Karyopharm Therapeutics Inc. has a market cap of $1.28 billion; its shares were traded at around $42.99 with and P/S ratio of 2149.50.

Karyopharm Therapeutics Inc. announced their 2014 first quarter results with revenues of $171,000 and net loss of $13.7 million.